Suppr超能文献

脯氨酰羟化酶抑制剂JNJ治疗促进糖尿病小鼠腹主动脉瘤进展。

Treatment with the Prolyl Hydroxylase Inhibitor JNJ Promotes Abdominal Aortic Aneurysm Progression in Diabetic Mice.

作者信息

Guo Jia, Shoji Tahakiro, Ge Yingbin, Zheng Xiaoya, Li Yankui, Zhao Sihai, Ikezoe Toru, Liu Shuai, Huang Jianhua, Wang Wei, Xu Baohui, Dalman Ronald L

机构信息

Department of Surgery, Stanford University School of Medicine, Stanford, CA, USA; Centre for Hypertension Care, Shanxi Medical University First Hospital, Taiyuan, Shanxi Province, P. R. China.

Department of Surgery, Stanford University School of Medicine, Stanford, CA, USA; Department of Emergency Medicine, Saiseikai Central Hospital, Minatoku, Tokyo, Japan.

出版信息

Eur J Vasc Endovasc Surg. 2022 Mar;63(3):484-494. doi: 10.1016/j.ejvs.2021.10.030. Epub 2021 Dec 3.

Abstract

OBJECTIVE

Prolyl hydroxylase domain containing proteins (PHD) rigorously regulate intracellular hypoxia inducible factor-1 (HIF-1) protein expression and activity. Diabetes impairs PHD activity and attenuates abdominal aortic aneurysm (AAA) progression. The extent to which dysregulated PHD activity contributes to diabetes mediated AAA suppression remains undetermined.

METHODS

AAAs were induced in diabetic and non-diabetic male C57BL/6J mice via intra-aortic elastase infusion. A PHD inhibitor (JNJ-42041935, aka "JNJ", 150 mmol/kg) or vehicle alone was administered daily starting one day prior to AAA induction for 14 days. Influences on AAA progression was assessed via ultrasonography and histopathology. Expression of aortic HIF-1α, three of its target genes and macrophage derived mediators were assayed via quantitative reverse transcription polymerase chain reaction. Aneurysmal sections from AAA patients with and without diabetes (two patients in each group) were immunostained for HIF-1α and vascular endothelial growth factor (VEGF)-A.

RESULTS

Expression of HIF-1α target genes (erythropoietin, VEGF-A, and glucose transporter-1) was reduced by 45% - 95% in experimental diabetic aortas. Diameter enlargement was similarly limited, as were mural elastin degradation, leukocyte infiltration, and neo-angiogenesis (reduced capillary density and length) on histopathology. Pre-treatment with JNJ prior to AAA initiation augmented aortic HIF-1α target gene expression and aneurysm progression in diabetic mice, along with macrophage VEGF-A and matrix metalloproteinase 2 mRNA expression. No differences were noted in HIF-1α or VEGF-A expression on aortic immunohistochemical staining of human aortic tissue as a function of diabetes status.

CONCLUSION

Small molecule PHD inhibitor treatment reduces or offsets impairment of experimental AAA progression in hyperglycemic mice, highlighting the potential contribution of dysregulated PHD activity to diabetes mediated aneurysm suppression.

摘要

目的

含脯氨酰羟化酶结构域蛋白(PHD)严格调控细胞内缺氧诱导因子-1(HIF-1)蛋白的表达和活性。糖尿病会损害PHD活性并减缓腹主动脉瘤(AAA)的进展。PHD活性失调在糖尿病介导的AAA抑制中所起的作用程度尚不确定。

方法

通过主动脉内注入弹性蛋白酶在糖尿病和非糖尿病雄性C57BL/6J小鼠中诱导AAA形成。从AAA诱导前一天开始,每天单独给予一种PHD抑制剂(JNJ-42041935,又名“JNJ”,150 mmol/kg)或赋形剂,持续14天。通过超声检查和组织病理学评估对AAA进展的影响。通过定量逆转录聚合酶链反应检测主动脉HIF-1α、其三个靶基因以及巨噬细胞衍生介质的表达。对有和没有糖尿病的AAA患者的动脉瘤切片(每组两名患者)进行HIF-1α和血管内皮生长因子(VEGF)-A免疫染色。

结果

在实验性糖尿病主动脉中,HIF-1α靶基因(促红细胞生成素、VEGF-A和葡萄糖转运蛋白-1)的表达降低了45% - 95%。直径增大同样受到限制,组织病理学上的壁弹性蛋白降解、白细胞浸润和新生血管形成(毛细血管密度和长度降低)也是如此。在AAA起始前用JNJ预处理可增强糖尿病小鼠主动脉HIF-1α靶基因表达和动脉瘤进展,以及巨噬细胞VEGF-A和基质金属蛋白酶2 mRNA表达。在人主动脉组织的主动脉免疫组织化学染色中,未发现HIF-1α或VEGF-A表达因糖尿病状态而存在差异。

结论

小分子PHD抑制剂治疗可减少或抵消高血糖小鼠实验性AAA进展的损害,突出了PHD活性失调对糖尿病介导的动脉瘤抑制的潜在作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验